Following unsatisfactory Phase 3 trial outcomes, Ultragenyx is compelled to implement cost reductions.

Sep 3, 2026, 9:20 AM ETTrialRead the original at benzinga.com

Bad for RARE

Phase 3 failure on primary and secondary endpoints and a pending program review plus planned expense reductions materially weaken the company's pipeline value and near-term financial prospects.

RARE · Ultragenyx Pharmaceutical Inc.

AI read · Bad for RARE

The AI's read

Ultragenyx's Phase 3 Aspire trial for apazunersen (GTX-102) failed to meet both its primary and key secondary endpoints, removing a major clinical and commercial catalyst. Management's stated program review and plans for significant expense reductions increase near-term downside risk to the company's pipeline value and financial outlook.

Get alerts for RARE

Follow Ultragenyx Pharmaceutical Inc. (RARE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RARE

Free on the App Store and Google Play, or on the web.